On the contrary, IDO-knockout mice treated with anti-CTLA-4 or anti-PD-1/PD-L1 demonstrate significant tumor growth regression and prolonged survival, and combination treatment of IDO inhibitors and CTLA-4 blockade has achieved remarkable tumor rejection (Holmgaard et al., 2013). This evidence concerns the gene CTLA4 and neoplasm.